dextrothyroxine has been researched along with Disbacteriosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deane, SM; Dicks, LMT; Grobbelaar, MJ | 1 |
| Belo, TCA; Corsetti, PP; de Almeida, LA; Oliveira, KC; Rosa, CP; Santos, AS; Santos, NCM; Souto, BS | 1 |
| Gonçalves, MVM; Nakaya, HI; Peron, JPS; Schlindwein, MAM | 1 |
| Cantacessi, C; Castro, C; Griffin, JL; Jenkins, TP; Molena, RA; Peachey, LE | 1 |
1 review(s) available for dextrothyroxine and Disbacteriosis
| Article | Year |
|---|---|
Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Dysbiosis; Gastrointestinal Microbiome; Ivermectin; SARS-CoV-2 | 2022 |
3 other study(ies) available for dextrothyroxine and Disbacteriosis
| Article | Year |
|---|---|
Ivermectin-induced bacterial gut dysbiosis does not increase susceptibility to Pseudomonas aeruginosa lung infection but exacerbates liver damage.
Topics: Animals; Dysbiosis; Ivermectin; Liver; Lung; Mice; Mice, Inbred C57BL; Pseudomonas aeruginosa | 2023 |
COVID-19 Pandemic and Dysbiosis: Can the Ivermectin Hysteria Lead to an Increase of Autoimmune Neuroinflammatory Diseases?
Topics: Autoimmune Diseases of the Nervous System; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Dysbiosis; Humans; Ivermectin; SARS-CoV-2 | 2020 |
Dysbiosis associated with acute helminth infections in herbivorous youngstock - observations and implications.
Topics: Animals; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Helminthiasis; Helminths; Herbivory; Horses; Ivermectin; Male | 2019 |